

## MATERIAL CHANGE REPORT FORM 51-102F3

**Item 1. Name and Address**

Love Pharma Inc. (the “**Company**” or “**Love**”)  
1780 - 355 Burrard Street  
Vancouver, BC V6C 2C8

**Item 2. Date of Material Change**

May 13, 2022

**Item 3. News Release**

The news release describing the material change was disseminated on May 13, 2022 through Accesswire and filed on SEDAR.

**Item 4. Summary of Material Change**

On May 13, 2022, the Company completed the acquisition of MicroDoz Therapy Inc. (“**MicroDoz**”) pursuant to a share exchange agreement (the “**Share Exchange Agreement**”) entered into among the Company, MicroDoz and the MicroDoz shareholders (the “**MicroDoz Shareholders**”).

**Item 5. Full Description of Material Change**

**5.1 *Full Description of Material Change***

On May 13, 2022, the Company completed the acquisition of MicroDoz pursuant to the Share Exchange Agreement entered into among the Company, MicroDoz and the MicroDoz Shareholders.

The Company issued to the MicroDoz Shareholders, on a pro-rata basis, 10,000,000 common shares of Love (the “**Love Shares**”) and will issue a further 10,000,000 Love Shares, subject to the fulfillment of certain milestones over a two (2) year period. All Love Shares issued pursuant to the Share Exchange Agreement are subject to a resale restricted period of four (4) months from the date of issuance and will bear a restrictive legend to this effect.

**5.2 *Disclosure for Restructuring Transactions***

Not applicable.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

No information has been omitted in respect of this material change.

**Item 8. Executive Officer**

The following executive officer of the Company is knowledgeable about the material change disclosed in this report and may be contacted as follows:

Zach Stadnyk, CEO and Director  
Telephone: (647) 980-7541

**Item 9. Date of Report**

May 24, 2022.